<DOC>
	<DOC>NCT01050517</DOC>
	<brief_summary>This randomised, controlled, double blinded clinical study investigates the safety and efficacy of the combination of albendazole, ivermectin and praziquantel in the treatment of children aged 5-18 years co-infected with lymphatic filariasis, schistosomiasis and soil-transmitted helminthiasis.</brief_summary>
	<brief_title>Safety and Efficacy of Drug Combinations Against Triple Infections</brief_title>
	<detailed_description />
	<mesh_term>Parasitic Diseases</mesh_term>
	<mesh_term>Albendazole</mesh_term>
	<mesh_term>Praziquantel</mesh_term>
	<mesh_term>Ivermectin</mesh_term>
	<criteria>Those who will be in class one to six by the time of study Aged 518 years and found infected with either SCH, any STH or LF for treatment groups 1,2 or 3 or infected with both SCH and LF for treatment group 4 and infected with all the three for treatment group 5 Who are willing and consent and whose parents will consent, will be included in the study. Those with acute and chronic diseases other than the targeted infections and those with a history of any serious adverse drug reactions will not be included in the study. Children with total bilirubin &gt; 50Âµmol/L and ALAT (Alanine transferase) &gt; 70IU/L will not qualify for recruitment.</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>